By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Investing > Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
Investing

Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval

News Room
Last updated: 2023/06/10 at 2:57 PM
By News Room
Share
1 Min Read
SHARE

Biogen Inc.
BIIB,
+1.31%
shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and Drug Administration advisory committee to approve an Alzheimer’s treatment it makes with Eisai Co.
ESALF,
+9.35%
Biogen shares rallied as much as 9% after hours, after spending the regular session halted at $308.88. Eisai shares finished Friday up 9.4% at $81.03. On Friday, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously to recommend the companies’ drug Leqembi to treat Alzheimer’s disease. While the FDA is not bound to committee recommendations, the agency generally follows them. Approval of the drug is expected by July 6.

Read the full article here

News Room June 10, 2023 June 10, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
French PM proposes scrapping national holidays and freezing spending to cut deficit

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Donald Trump announces trade deal with Indonesia

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Nvidia and Jane Street back Mira Murati’s AI start-up in latest fundraising

Stay informed with free updatesSimply sign up to the Artificial intelligence myFT…

How one of the gravest security lapses in history was kept secret

It was a lawsuit unlike any other. On August 25, 2023, just…

BlackRock inflows hit after big client withdraws $52bn

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Nursing Home Stocks Could Suffer from this Medicaid Spending Remedy

By News Room
Investing

Bitcoin Drops Below $90,000 Again. What Could Move It Next.

By News Room
Investing

These Stocks Are Moving the Most Today: Marvell, Nvidia, Broadcom, GM, Tesla, MongoDB, Burlington, and More

By News Room
Investing

Nvidia Stock Falls as Marvell Earnings Compound AI Gloom. The Rising Risks for Chips.

By News Room
Investing

This analyst says Tesla deliveries will be 16% below expectations. Musk is part of the problem.

By News Room
Investing

BP CEO was awarded no bonus pay from oil giant’s financial performance

By News Room
Investing

Shares of Starlink’s European competitor have tripled. CEO says it can do the job in Ukraine.

By News Room
Investing

GE Vernova Stock Rises as Analyst Flips to Upgrade After Rating Cut

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?